Frontier neuroscience is full of breakthroughs. But turning those discoveries into viable companies, ones that endure scientific scrutiny, solve meaningful problems, and earn trust, is a different kind of challenge.

That challenge was at the heart of the inaugural Neuro-inspired Computation and Entrepreneurship Workshop, co-hosted by the Corundum Convergence Institute (CCI) and the University of Tokyo’s International Research Center for Neurointelligence (IRCN) earlier this summer.

Held on the University of Tokyo campus, the workshop was a joint effort to demystify the early-stage journey for scientists who see entrepreneurial potential in their work, but might not yet have the playbook for translating it into impact.

Sessions opened up space for hard questions and candid reflections: What makes an idea investable? How do you stay grounded in the patient experience while pushing the boundaries of science? What does it take to move from compelling research to a venture that can scale and succeed?

Here are a few moments that stood out, and might offer inspiration for others navigating the path from research to real-world impact.

Launching a neuroscience startup means navigating complexity on every front. Dr. Alain Prochiantz (Co-founder and CSO of BrainEver) reminded us that scientific excellence is only the starting point and that strong IP, credible communication, and executional clarity are just as essential. Dr. Elisa Ferrari (Founder and CEO of QuantaBrain) showed how AI might help fix clinical trial attrition, but only if built on high-quality, neuro-specific data and explainable models. Ferrari underscored that generic AI won’t cut it in neuroscience, where the stakes are high and trust is hard-won.

According to Shinichiro Komoto (Partner at Eight Roads), good venture capital doesn’t chase hype, it looks for thoughtful alignment between vision, market, and execution. It’s not about pitching the biggest market or boldest claim; it’s about showing how your specific insight fits the need, and how your team is built to deliver. Komoto also noted that Japan’s biotech sector is at an inflection point, with strong science but limited international visibility, and encouraged founders to think cross-border from day one.

CCI’s own Shunsuke Nagao expanded the conversation to startup exit scenarios. Exploring the different paths to exit, he highlighted the importance of adaptability in a dynamic marketplace and emphasized that successful outcomes are shaped long before an IPO or M&A.

If you’re not thinking about end users from day one, you’re already behind. That was the clear takeaway from Ian Burkhart (President of The Ian Burkhart Foundation) and Jojo Platt (President of Platt & Associates). They challenged founders to build with empathy, realism, and shared purpose. Ian’s experience as a patient in a pioneering BCI trial reinforced why autonomy, dignity, and trust can’t be afterthoughts. He cautioned that too many neurotech solutions are still built for patients rather than with them, leaving critical design considerations overlooked until it’s too late. Jojo's message was to design with the full timeline in mind – regulatory hurdles, funding gaps, emotional wear-and-tear. This field demands stamina and heart.

A foundational session led by Maria Guo’s team from Harvard’s Lemann Program on Creativity and Entrepreneurship (LPCE) reframed startup formation as a discipline in focused problem-solving. The session challenged participants to clarify their intent: Why are you building this? Who is it for? What does meaningful success look like?

The session served as a reminder that rigor at the foundation, through precise questions, deliberate collaboration, and measured ambition, is what makes bold ideas executable.

Sessions led by Devang Thakor (President of Anioplex), Yasuyuki Oikawa (COO of Amplified.ai), Kenichi Nogami (CFO of Infcurion), and Jed Barron (Managing Director of Accolade) tackled the often overlooked but make-or-break areas of company building. As Barron put it, “At the earliest stage, it's not about revenue or size - it's about trust, alignment, and potential. People invest in you, not your numbers.” Across topics was one consistent theme: strategic decisions carry scientific weight. Every clause in a patent, narrative choice in a pitch, and timeline assumption in a business model shapes how a venture takes form.

Together with IRCN, we set out to create something immersive and actionable: a starting point for researchers curious about what it takes to go from idea to impact. For some, it was their first exposure to entrepreneurship. For others, a chance to sharpen their thinking on how their work might reach the real world.

Across each session, one thing stood out – world-class neuroscience isn’t enough. Real impact requires more. It takes storytelling, thoughtful design, and the willingness to build and adapt. It needs people – scientists, operators, and investors – who are ready to challenge their assumptions and do the hard work of translation.

At CCI, we believe science should move from the bench into the world. Our partnership with IRCN is one example of how we’re building the connective tissue between discovery and deployment, helping the next generation of founder-scientists explore what’s possible. If the energy in the room was any indication, this is just the beginning.